Table 3 |
||||
|
Additional gastrointestinal bleeding events and myocardial infarction associated with using NSAIDs and coxibs |
||||
|
Event and drug |
Relative risk |
Additional events per 1,000 |
Additional deaths per 1,000 |
Frequency (1 in) |
|
|
||||
|
Gastrointestinal bleeding (background rate 2.2 per 1,000) |
||||
|
Ibuprofen |
1.9 |
1.98 |
0.20 |
5,051 |
|
Naproxen |
4.0 |
6.60 |
0.66 |
1,515 |
|
Diclofenac |
3.3 |
5.06 |
0.51 |
1,976 |
|
All NSAIDs |
4.2 |
7.04 |
0.70 |
1,420 |
|
Celecoxib |
1.1 |
0.22 |
0.02 |
45,455 |
|
Rofecoxib |
2.0 |
2.20 |
0.22 |
4,545 |
|
Myocardial infarction (background rate 8.2 per 1,000) |
||||
|
Ibuprofen |
1.07 |
0.57 |
0.17 |
5,807 |
|
Naproxen |
0.98 |
-0.16 |
-0.05 |
-20,325 |
|
Diclofenac |
1.44 |
3.61 |
1.08 |
924 |
|
All NSAIDs |
1.09 |
0.74 |
0.22 |
4,517 |
|
Celecoxib |
0.96 |
-0.33 |
-0.10 |
-10,163 |
|
Rofecoxib |
1.26 |
2.13 |
0.64 |
1,563 |
|
|
||||
|
Any dose of drug was allowed in the data, and the table additionally shows the rate and frequency of additional events. The calculations used a mortality rate of 10% for gastrointestinal bleeding and 30% for cardiovascular events. NSAID, non-steroidal anti-inflammatory drug; coxib, cyclooxygenase-2 inhibitor. |
||||
|
Moore et al. Arthritis Research & Therapy 2008 10:R20 doi:10.1186/ar2373 |
||||